Estrella Immunopharma Adds Fifth Site for Phase I/II EB103 Trial in B — Cell Non — Hodgkin’s Lymphoma
Estrella Immunopharma activated Intermountain Health LDS Hospital as the fifth site for its Phase I/II STARLIGHT-1 trial of EB103. The Salt Lake City hospital is expected to begin screening and enrolling patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma following site initiation. The ongoing expansion